Leerink Partnrs Issues Positive Outlook for THC Earnings

Tenet Healthcare Co. (NYSE:THC - Free Report) - Equities research analysts at Leerink Partnrs increased their Q2 2025 earnings per share estimates for shares of Tenet Healthcare in a research note issued on Tuesday, June 3rd. Leerink Partnrs analyst W. Mayo now forecasts that the company will post earnings of $2.91 per share for the quarter, up from their previous forecast of $2.90. The consensus estimate for Tenet Healthcare's current full-year earnings is $12.24 per share. Leerink Partnrs also issued estimates for Tenet Healthcare's FY2025 earnings at $12.56 EPS, Q1 2026 earnings at $3.84 EPS, Q2 2026 earnings at $3.54 EPS, FY2028 earnings at $24.63 EPS and FY2029 earnings at $27.02 EPS.

Tenet Healthcare (NYSE:THC - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $4.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.11 by $1.25. Tenet Healthcare had a return on equity of 21.88% and a net margin of 15.48%. The firm had revenue of $5.22 billion for the quarter, compared to analysts' expectations of $5.15 billion. During the same period last year, the business posted $3.22 earnings per share. The firm's revenue for the quarter was down 2.5% on a year-over-year basis.

Other equities analysts have also issued reports about the company. Guggenheim assumed coverage on Tenet Healthcare in a report on Wednesday, April 9th. They set a "buy" rating and a $165.00 target price for the company. Wells Fargo & Company upgraded Tenet Healthcare from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $150.00 to $195.00 in a research note on Thursday, May 29th. Truist Financial upped their price target on shares of Tenet Healthcare from $175.00 to $190.00 and gave the stock a "buy" rating in a research report on Monday, May 12th. TD Cowen initiated coverage on shares of Tenet Healthcare in a research note on Wednesday, February 26th. They set a "buy" rating and a $175.00 target price for the company. Finally, Robert W. Baird restated a "neutral" rating and issued a $137.00 price target (down previously from $153.00) on shares of Tenet Healthcare in a research note on Tuesday, April 15th. Three investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $180.18.

Tenet Healthcare Stock Performance

Shares of NYSE:THC traded up $1.77 during trading on Thursday, reaching $171.66. 1,277,534 shares of the company's stock traded hands, compared to its average volume of 1,525,253. The company has a debt-to-equity ratio of 2.25, a current ratio of 1.78 and a quick ratio of 1.70. The company has a 50 day moving average of $142.93 and a 200-day moving average of $136.84. Tenet Healthcare has a 12 month low of $109.82 and a 12 month high of $174.14. The stock has a market capitalization of $15.94 billion, a P/E ratio of 5.33, a price-to-earnings-growth ratio of 1.02 and a beta of 1.65.

Insider Transactions at Tenet Healthcare

In other Tenet Healthcare news, Director James L. Bierman sold 13,836 shares of the business's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $159.58, for a total value of $2,207,948.88. Following the sale, the director now directly owns 41,435 shares in the company, valued at approximately $6,612,197.30. The trade was a 25.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard W. Fisher sold 3,077 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $165.72, for a total transaction of $509,920.44. Following the completion of the sale, the director now owns 12,128 shares in the company, valued at $2,009,852.16. The trade was a 20.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,072 shares of company stock valued at $8,557,590. Corporate insiders own 0.81% of the company's stock.

Institutional Investors Weigh In On Tenet Healthcare

Hedge funds have recently modified their holdings of the stock. Blue Trust Inc. lifted its stake in Tenet Healthcare by 172.3% during the fourth quarter. Blue Trust Inc. now owns 689 shares of the company's stock valued at $87,000 after buying an additional 436 shares in the last quarter. Spire Wealth Management lifted its position in shares of Tenet Healthcare by 19.5% in the 4th quarter. Spire Wealth Management now owns 558 shares of the company's stock valued at $70,000 after acquiring an additional 91 shares in the last quarter. Trust Point Inc. purchased a new position in Tenet Healthcare during the 4th quarter worth approximately $223,000. abrdn plc raised its stake in Tenet Healthcare by 29.0% during the 4th quarter. abrdn plc now owns 98,229 shares of the company's stock valued at $12,320,000 after purchasing an additional 22,066 shares during the period. Finally, Optimist Retirement Group LLC boosted its position in shares of Tenet Healthcare by 20.3% in the fourth quarter. Optimist Retirement Group LLC now owns 1,965 shares of the company's stock worth $248,000 after buying an additional 331 shares during the period. 95.44% of the stock is owned by hedge funds and other institutional investors.

About Tenet Healthcare

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.